{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-041541","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.134312+00:00","generated_at":"2026-05-31T00:57:15.625450+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026","bullets":["Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.","Up to >$3.5B in milestones ($1.4B development, >$2.1B commercialization) plus tiered royalties; BMS locked up shares until Sep 2027.","Pipeline focus: Phase 1/2 CGD data expected in 2025; Wilson's Disease IND/CTA planned for H1 2026.","X-linked CGD program added using PASSIGE technology; cystic fibrosis work continues with CFF funding.","Cost savings plus BMS upfront extend cash runway into first half of 2026 (previously not guided beyond 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-041541","json":"https://secwatch.observer/filing/0001628280-24-041541.json","markdown":"https://secwatch.observer/filing/0001628280-24-041541.md","text":"https://secwatch.observer/filing/0001628280-24-041541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/0001628280-24-041541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/prme-20240928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:57:15.625450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}